Compositions and methods for treatment of liquid cancers
Grant
US12594301B2
Kind: B2
Apr 07, 2026
Assignee
Beam Therapeutics Inc.
Inventors
Jason Michael Gehrke, Aaron D. Edwards, Ryan Murray, Waseem Qasim
Abstract
As described below, the present invention features genetically modified immune cells having enhanced anti-neoplasia activity, resistance to immune suppression, and decreased risk of eliciting a graft versus host reaction, or a combination thereof. The present invention also features methods for producing and using these modified immune effector cells.
CPC Classifications
A61K 35/12
A61K 40/11
A61K 40/22
A61K 40/31
A61K 40/418
A61K 40/4224
A61K 2035/124
C12N 5/0636
C12N 2510/00
C07K 14/705
Filing Date
2020-09-25
Application No.
17762690
Claims
12